Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on pharmaceuticals.

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, a move that would save the company $1 billion over the next two years. Additionally, the company spun off its generics ...

As a result, Moberg Pharma expects to have several alternate terbinafine suppliers secured in the near future. Each of these suppliers has the capacity to meet the company's global terbinafine demand.

Novartis is paying Generate:Biomedicines $65 million up front in an AI drug development deal, and milestone payments could exceed $1 billion.

Novartis failed to convince a federal court to block generic drugmaker MSN Pharmaceuticals from launching its own version of Novartis' blockbuster heart-failure drug Entresto, according to a court ...

A Novartis executive said “it’s too early to say” whether the company would submit an experimental myelofibrosis drug for approval this year, amid questions about the medicine’s data profile.

Novartis paid an undisclosed upfront fee to form the original PDC pact. Now, the Swiss drugmaker has put down a further $180 million and offered up to $2.71 billion in milestones to expand the ...

Key takeaways: Treatment efficacy was achieved by 76.67% of the continuous regimen group vs. 26.67% of the pulsed group (P = .001).The authors recommended daily, continuous usage of terbinafine in ...